The city of Austin, Texas, currently has 12 active clinical trials seeking participants for Anxiety research studies.
Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety
NCT05427708
Recruiting
Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Texas at Austin, Austin, Texas
Conditions: Anxiety Disorders, Trauma, Generalized Anxiety Disorder, Panic Disorder, Agoraphobia, Illness Anxiety Disorder, Social Anxiety Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, Adjustment Disorder With Anxious Mood
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
NCT06741228
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/15/2025
Locations: Dell Medical School, University of Texas at Austin, Austin, Texas +2 locations
Conditions: Generalized Anxiety Disorder
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595
Recruiting
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/15/2025
Locations: Austin Clinical Trial Partners, Austin, Texas
Conditions: Generalized Anxiety Disorder
Register for Updates
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
NCT05467683
Recruiting
Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/18/2025
Locations: The University of Texas at Austin, Austin, Texas
Conditions: Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
NCT06615557
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Vistagen Clinical Site, Austin, Texas +1 locations
Conditions: Social Anxiety Disorder (SAD)
Register for Updates
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
NCT06510504
Recruiting
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2025
Locations: AFFIRM-1 Study Site, Austin, Texas
Conditions: Social Anxiety Disorder
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Psychiatry and Psychotherapy Partners Austin, Austin, Texas
Conditions: Generalized Anxiety Disorder
Register for Updates
Multisite Virtual Reality Intervention for Speech Anxiety
NCT06593847
Recruiting
Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: University of Texas at Austin, Austin, Texas
Conditions: Public Speaking, Speech Anxiety
Register for Updates
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Austin, Texas +1 locations
Conditions: Generalized Anxiety Disorder
Register for Updates
Testing FIRST in Youth Outpatient Psychotherapy
NCT04725721
Recruiting
The study will compare the impact FIRST (a transdiagnostic treatment built upon five empirically supported principles of change) versus usual care outpatient psychotherapy on youths' mental health outcomes and a candidate mechanism of change: regulation of negative emotions.
Gender:
ALL
Ages:
Between 7 years and 15 years
Trial Updated:
10/08/2024
Locations: University of Texas at Austin, Austin, Texas
Conditions: Anxiety, Depression, Trauma, Behavior Problem
Register for Updates
ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder
NCT05749055
Recruiting
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/29/2024
Locations: Austin Clinical Trials Partners, Austin, Texas
Conditions: Generalized Anxiety Disorder
Register for Updates
Neuroimaging Memories of Fear and Safety in the Human Brain
NCT04975009
Recruiting
The purpose of this research is to use functional magnetic resonance imaging (fMRI) to investigate how the brain forms associations between neutral and negative stimuli. The ultimate goal is to understand the neural systems involved in regulating negative emotional responses to fearful stimuli.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/16/2022
Locations: The University of Texas at Austin, Austin, Texas +1 locations
Conditions: Fear Anxiety, PTSD
Register for Updates